Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings

Jian Hua Luo*, Silvia Liu, Junyan Tao, Bao Guo Ren, Katherine Luo, Zhang Hui Chen, Michael Nalesnik, Kathleen Cieply, Tianzhou Ma, Shi Yuan Cheng, Qi Chen, George K. Michalopoulos, Joel B. Nelson, Rohit Bhargava, Jun Zhang, Deqin Ma, David Jarrard, Arjun Pennathur, James D. Luketich, Donald B. DeFrancoSatdarshan Paul Monga, George Tseng, Yan Ping Yu

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Inactivation of Pten gene through deletions and mutations leading to excessive pro-growth signaling pathway activations frequently occurs in cancers. Here, we report a Pten derived pro-cancer growth gene fusion Pten-NOLC1 originated from a chr10 genome rearrangement and identified through a transcriptome sequencing analysis of human cancers. Pten-NOLC1 fusion is present in primary human cancer samples and cancer cell lines from different organs. The product of Pten-NOLC1 is a nuclear protein that interacts and activates promoters of EGFR, c-MET, and their signaling molecules. Pten-NOLC1 promotes cancer proliferation, growth, invasion, and metastasis, and reduces the survival of animals xenografted with Pten-NOLC1-expressing cancer cells. Genomic disruption of Pten-NOLC1 induces cancer cell death, while genomic integration of this fusion gene into the liver coupled with somatic Pten deletion produces spontaneous liver cancers in mice. Our studies indicate that Pten-NOLC1 gene fusion is a driver for human cancers.

Original languageEnglish (US)
Pages (from-to)1064-1076
Number of pages13
Issue number6
StatePublished - Feb 11 2021

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings'. Together they form a unique fingerprint.

Cite this